GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adynxx Inc (FRA:HL1C) » Definitions » Short Interest

Adynxx (FRA:HL1C) Short Interest


View and export this data going back to 1998. Start your Free Trial

What is Adynxx Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Adynxx's Short Interest

For the Biotechnology subindustry, Adynxx's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adynxx's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adynxx's Short Interest distribution charts can be found below:

* The bar in red indicates where Adynxx's Short Interest falls into.


Adynxx (FRA:HL1C) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adynxx Inc (FRA:HL1C) » Definitions » Short Interest
Comparable Companies
TRPX MITI RASP USRM BDPT VBIO BTHE SGBI TIKRF BZYR OCSE:NOVO B ASX:CSL VRTX REGN XKRX:207940 SGEN MRNA ALXN XKRX:068270 INCY
Traded in Other Exchanges
N/A
Address
100 Pine Street, Suite 500, San Francisco, CA, USA, 94111
Website
http://www.adynxx.com
Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.

Adynxx (FRA:HL1C) Headlines

No Headlines